The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Elevated pretreatment serum biomarkers and correlation with progression-free (PFS) and overall survival (OS) in first-line trastuzumab-treated metastatic breast cancer.
Suhail M. Ali
No relevant relationships to disclose
Kim Leitzel
No relevant relationships to disclose
Uchechi Anyanwu
No relevant relationships to disclose
Hui Ying Hou
No relevant relationships to disclose
Matthew Stephen Evans
No relevant relationships to disclose
Vikas Shrivastava
No relevant relationships to disclose
Wolfgang Köstler
No relevant relationships to disclose
Eva-Maria Fuchs
No relevant relationships to disclose
Francisco J. Esteva
No relevant relationships to disclose
Walter P. Carney
Employment or Leadership Position - Wilex
Allan Lipton
No relevant relationships to disclose